Suppliers and packagers for CARBOPLATIN

CARBOPLATIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	CARBOPLATIN	carboplatin	INJECTABLE;INTRAVENOUS	206775	ANDA	Accord Healthcare, Inc.	16729-295-12	1 VIAL, MULTI-DOSE in 1 CARTON (16729-295-12) / 60 mL in 1 VIAL, MULTI-DOSE	2017-09-19
Accord Hlthcare	CARBOPLATIN	carboplatin	INJECTABLE;INTRAVENOUS	206775	ANDA	Accord Healthcare, Inc.	16729-295-31	1 VIAL, MULTI-DOSE in 1 CARTON (16729-295-31) / 5 mL in 1 VIAL, MULTI-DOSE	2017-09-19
Accord Hlthcare	CARBOPLATIN	carboplatin	INJECTABLE;INTRAVENOUS	206775	ANDA	Accord Healthcare, Inc.	16729-295-33	1 VIAL, MULTI-DOSE in 1 CARTON (16729-295-33) / 15 mL in 1 VIAL, MULTI-DOSE	2017-09-19

Carboplatin Drug Supplier Landscape

Last updated: February 19, 2026

Carboplatin is a platinum-based chemotherapy drug used to treat various cancers, including ovarian, lung, and head and neck cancers. Its production relies on a specialized supply chain due to the complex synthesis and stringent quality control requirements for active pharmaceutical ingredients (APIs). The market for carboplatin API is characterized by established manufacturers, particularly in Asia, serving global generic drug producers.

Who are the primary manufacturers of Carboplatin API?

The production of carboplatin API is concentrated among a limited number of global manufacturers. These companies possess the specialized chemical synthesis capabilities and adhere to Good Manufacturing Practices (GMP) necessary for pharmaceutical-grade production.

• Asia Dominates Production: The majority of carboplatin API manufacturers are located in India and China. These regions have developed robust chemical synthesis infrastructure and offer competitive pricing.
• Key Players: Specific manufacturers include, but are not limited to:
  • Hospira, Inc. (now part of Pfizer): Historically a significant supplier, though its API manufacturing has evolved with acquisitions.
  • Fresenius Kabi AG: A prominent player in sterile injectables and APIs.
  • Pfizer Inc.: Maintains a significant presence in oncology and API production.
  • Sun Pharmaceutical Industries Ltd.: A large Indian pharmaceutical company with extensive API manufacturing capabilities.
  • Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical company involved in API production for oncology drugs.
  • Cipla Ltd.: An Indian multinational pharmaceutical company that manufactures APIs.
  • Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, which often involves in-house or contracted API production.

Data on specific production volumes and market share for individual API manufacturers of carboplatin is not publicly disclosed in detail. However, regulatory filings and industry reports indicate these companies are consistently involved in the supply chain.

What are the regulatory requirements for Carboplatin API production?

The production and supply of carboplatin API are subject to strict regulatory oversight by health authorities worldwide to ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All manufacturers must comply with GMP standards established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. These standards cover facility design, equipment, personnel, manufacturing processes, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and quality control of the API. Generic drug manufacturers reference these DMFs in their drug product applications.
• Inspections and Audits: Manufacturing facilities are subject to regular inspections by regulatory authorities and audits by customers (drug product manufacturers) to ensure ongoing compliance.
• Pharmacopeial Standards: Carboplatin API must meet the specifications outlined in official pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, assay, and impurity limits.
• Impurity Profiling: Stringent control over impurities, particularly platinum-related byproducts and residual solvents, is critical. Regulatory bodies require detailed impurity profiles and validated analytical methods for their detection and quantification.

For example, USP <232> and <233> (Elemental Impurities) and ICH Q3D guidelines set limits for elemental impurities that are applicable to API manufacturing, including carboplatin.

How is the Carboplatin API supply chain structured?

The carboplatin API supply chain involves a series of steps from raw material sourcing to the final API delivered to drug product manufacturers.

• Raw Material Sourcing: The synthesis of carboplatin begins with platinum salts and other chemical precursors. Sourcing high-purity platinum is a critical upstream component.
• API Synthesis: Specialized chemical manufacturers perform multi-step synthesis reactions to produce bulk carboplatin API. This process requires controlled environments and specialized equipment.
• Quality Control and Testing: The synthesized API undergoes rigorous testing to confirm its identity, purity, potency, and freedom from contaminants. This testing is performed by the API manufacturer and often independently verified by the drug product manufacturer.
• Packaging and Storage: The API is packaged in containers that protect its integrity and stored under controlled conditions to maintain stability.
• Distribution: The API is then shipped to generic drug product manufacturers who formulate it into injectable dosage forms.

The complexity of platinum chemistry and the highly regulated nature of pharmaceutical manufacturing mean that the number of qualified carboplatin API suppliers is relatively limited.

What are the key considerations for sourcing Carboplatin API?

Pharmaceutical companies seeking to manufacture carboplatin drug products must carefully evaluate potential API suppliers based on several critical factors.

• Regulatory Compliance: Ensuring the supplier has a strong regulatory track record, including successful FDA and EMA inspections and up-to-date DMFs, is paramount.
• Quality Assurance: The supplier's quality management system, including its adherence to GMP, change control processes, and batch-to-batch consistency, must be robust.
• Supply Chain Reliability: The ability of the supplier to consistently deliver product on time and in the required quantities is essential to avoid drug shortages. This includes assessing their raw material sourcing and production capacity.
• Cost-Effectiveness: While quality and reliability are primary, competitive pricing is also a significant factor, especially in the generic drug market.
• Technical Support: The supplier should be able to provide comprehensive technical support, including documentation, analytical method transfer, and assistance with regulatory filings.
• Geopolitical and Economic Stability: The geopolitical stability of the supplier's region and the economic factors influencing raw material costs and transportation can impact supply.

For instance, a drug product manufacturer might conduct a thorough supplier qualification audit that includes on-site inspections, review of quality agreements, and assessment of the supplier's business continuity plans.

What is the projected market outlook for Carboplatin API?

The market for carboplatin API is influenced by the global demand for carboplatin-based cancer treatments and the dynamics of the generic pharmaceutical industry.

• Stable Demand: The use of carboplatin in established oncology treatment regimens provides a baseline demand. Cancer incidence rates and aging populations continue to drive demand for chemotherapy drugs.
• Generic Market Competition: The carboplatin market is largely driven by generic competition, which puts pressure on API pricing. Manufacturers focus on efficiency and cost control.
• Emerging Markets: Growing healthcare infrastructure and access to cancer treatment in emerging markets can lead to increased demand for carboplatin.
• Technological Advancements: While the core synthesis of carboplatin is well-established, ongoing efforts in process optimization and impurity control can impact manufacturing costs and quality.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Companies are increasingly looking to diversify their supplier base or ensure strong relationships with key, reliable partners.

The global market size for carboplatin API is not always separately reported but is typically subsumed within the broader platinum-based chemotherapy API market. Estimates for the overall platinum-based chemotherapy API market vary, but it is considered a mature segment with consistent demand.

How do Carboplatin and Cisplatin APIs differ in their supply chains?

While both carboplatin and cisplatin are platinum-based chemotherapy drugs, their API supply chains share some commonalities but also exhibit distinct characteristics driven by chemical properties and therapeutic applications.

• Chemical Synthesis Complexity:
  • Carboplatin: Synthesis involves cyclobutane-1,1-dicarboxylate ligands, requiring specific precursor chemicals and reaction conditions.
  • Cisplatin: Synthesis involves ammonia ligands and chloride, with reactions often conducted in aqueous solutions.
  • Shared Precursors: Both ultimately derive from platinum metal, with platinum(II) or platinum(IV) salts serving as initial starting materials.
• Impurity Profiles:
  • Carboplatin: Key impurities can include platinum-containing byproducts from incomplete reactions, degradation products, and residual solvents. Control of platinum species is critical.
  • Cisplatin: Impurities may include transplatin (its less active isomer), platinum oxides, and other platinum complexes formed under varying conditions.
• Stability:
  • Carboplatin: Generally considered more stable than cisplatin, particularly in solution, which can simplify formulation and storage requirements for the API.
  • Cisplatin: Can be more sensitive to light and certain pH conditions, requiring more stringent handling and storage for the API and drug product.
• Manufacturing Scale and Specialization:
  • While some manufacturers may produce both APIs, the specialized nature of platinum chemistry means that facilities equipped for one may not be immediately suitable for the other without adjustments.
  • The volume of production for each can differ based on their respective clinical uses. Cisplatin has been used longer and in a wider array of indications historically, though carboplatin's improved tolerability has led to significant uptake.
• Regulatory Scrutiny: Both APIs face intense regulatory scrutiny. However, differences in their degradation pathways and impurity profiles mean that specific analytical methods and specifications may differ between their pharmacopeial monographs. For example, USP and Ph. Eur. monographs for each drug detail specific tests for related substances and impurities.

In essence, while the upstream sourcing of platinum and the overarching GMP requirements are shared, the specific chemical synthesis routes, impurity control strategies, and stability considerations create distinct supply chain management challenges and opportunities for carboplatin API compared to cisplatin API.

Key Takeaways

• Carboplatin API manufacturing is dominated by companies in Asia, notably India and China.
• Regulatory compliance, particularly adherence to GMP and the maintenance of Drug Master Files, is critical for API suppliers.
• The supply chain involves specialized synthesis, stringent quality control, and distribution to generic drug product manufacturers.
• Key sourcing considerations include regulatory standing, quality assurance, supply reliability, and cost.
• The market outlook is stable, driven by ongoing cancer treatment needs and generic competition, with potential growth in emerging markets.
• Carboplatin API supply chains differ from cisplatin API in their specific synthesis routes, impurity profiles, and stability characteristics, despite shared reliance on platinum precursors.

Frequently Asked Questions

• What is the typical lead time for procuring bulk carboplatin API from a qualified supplier? Lead times can range from 4 to 12 weeks, depending on the supplier's production schedule, inventory levels, and the specific quantities ordered. Established relationships can sometimes facilitate shorter lead times.

• Are there specific geographic regions that represent a higher risk for carboplatin API supply chain disruptions? Geopolitical instability, stringent environmental regulations affecting chemical manufacturing, and trade policy shifts in major producing regions like China and India can pose risks. Dependence on a single region or supplier amplifies this risk.

• What analytical methods are most critical for verifying the quality of carboplatin API? High-performance liquid chromatography (HPLC) is essential for assay and impurity profiling. Inductively coupled plasma mass spectrometry (ICP-MS) or atomic absorption spectroscopy (AAS) are used for elemental impurity analysis, particularly for residual platinum. Techniques like Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) are used for identification.

• How does the patent landscape impact the sourcing of carboplatin API? Carboplatin itself is a well-established drug with its composition of matter patents long expired. The patent landscape primarily affects the sourcing of API by influencing process patents for novel or improved synthesis methods, or patents related to specific polymorphic forms or purification techniques. However, for generic API production, focus is on non-infringing, cost-effective manufacturing processes.

• What are the primary quality agreements between a carboplatin API supplier and a drug product manufacturer? Quality agreements typically detail responsibilities for GMP compliance, change control procedures, handling of deviations and OOS (out-of-specification) results, batch release responsibilities, audit rights, product specifications, and procedures for handling product complaints or recalls.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/inspections-compliance-enforcement-and-biologics/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/manufacturing-medicines

[3] United States Pharmacopeial Convention. (n.d.). USP General Chapters. Retrieved from https://www.uspnf.com/official-text/current/general-chapters

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines